The tau immunotherapy reduced tau and Aβ burden in both sexes but the therapeutic benefits were generally more pronounced in females, although they have more pronounced pathology, which fits our prior findings in a different tauopathy model7. This evidence concerns the gene MAPT and tauopathy.